Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration
Repare Therapeutics(US:RPTX) Businesswire·2025-12-24 12:00交易公告 - 临床阶段精准肿瘤学公司Repare Therapeutics Inc与吉利德科学公司达成了一项最终资产购买协议 [1] - 吉利德科学公司将收购Repare公司的聚合酶θ抑制剂RP-3467 [1] - 该交易结合了吉利德在肿瘤研发领域的领先专长与RP-3467这款潜在同类最佳的资产 [1]